Health Secur. 2017 Nov/Dec;15(6):620-628. doi: 10.1089/hs.2017.0061. Epub 2017 Aug 24.
In March 2017, the American biotech company Tonix announced that a Canadian scientist had synthesized horsepox virus as part of a project to develop a safer vaccine against smallpox. The first de novo synthesis of an orthopoxvirus, a closely related group of viruses that includes horsepox and the variola virus that causes smallpox, crosses an important Rubicon in the field of biosecurity. The synthesis of horsepox virus takes the world one step closer to the reemergence of smallpox as a threat to global health security. That threat has been held at bay for the past 40 years by the extreme difficulty of obtaining variola virus and the availability of effective medical countermeasures. The techniques demonstrated by the synthesis of horsepox have the potential to erase both of these barriers. The primary risk posed by this research is that it will open the door to the routine and widespread synthesis of other orthopoxviruses, such as vaccinia, for use in research, public health, and medicine. The normalization and globalization of orthopoxvirus synthesis for these beneficial applications will create a cadre of laboratories and scientists that will also have the capability and expertise to create infectious variola virus from synthetic DNA. Unless the safeguards against the synthesis of variola virus are strengthened, the capability to reintroduce smallpox into the human population will be globally distributed and either loosely or completely unregulated, providing the foundation for a disgruntled or radicalized scientist, sophisticated terrorist group, unscrupulous company, or rogue state to recreate one of humanity's most feared microbial enemies. The reemergence of smallpox-because of a laboratory accident or an intentional release-would be a global health disaster. International organizations, national governments, the DNA synthesis industry, and the synthetic biology community all have a role to play in devising new approaches to preventing the reemergence of smallpox.
2017 年 3 月,美国生物技术公司 Tonix 宣布,一位加拿大科学家已经合成了马痘病毒,作为开发更安全的天花疫苗项目的一部分。正痘病毒的首次从头合成,这是一组密切相关的病毒,包括马痘和引起天花的天花病毒,标志着生物安全领域的一个重要突破。马痘病毒的合成使世界离天花重新成为全球健康安全威胁又近了一步。过去 40 年来,由于难以获得天花病毒以及有效的医疗对策,这一威胁一直得以遏制。马痘病毒合成所展示的技术有可能消除这两个障碍。这项研究的主要风险是,它将为常规和广泛合成其他正痘病毒(如牛痘病毒)打开大门,用于研究、公共卫生和医学。正痘病毒合成的正常化和全球化,将为这些有益的应用创造一个实验室和科学家的核心团队,他们也将有能力和专业知识从合成 DNA 中创建传染性天花病毒。除非加强对天花病毒合成的防范,否则将天花重新引入人类的能力将在全球范围内传播,而且可能是松散的或完全不受监管的,为心怀不满或激进的科学家、复杂的恐怖组织、肆无忌惮的公司或流氓国家重新创造人类最可怕的微生物敌人之一提供了基础。由于实验室事故或故意释放,天花的再次出现将是一场全球健康灾难。国际组织、各国政府、DNA 合成行业和合成生物学界都可以在设计新方法防止天花再次出现方面发挥作用。